These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: THRIVE-c score predicts clinical outcomes in Chinese patients after thrombolysis.
    Author: Pan Y, Peng Y, Chen W, Wang Y, Lin Y, He Y, Wang N, Wang Y.
    Journal: Brain Behav; 2018 Feb; 8(2):e00927. PubMed ID: 29484275.
    Abstract:
    OBJECTIVES: Total Health Risks in Vascular Events-calculation score (THRIVE-c) is an easy use and patient-specific outcome predictive score by computing the logistic equation with patients' continuous variables. We validated its performance in Chinese ischemic stroke patients receiving intravenous thrombolysis (IVT) therapy. MATERIALS AND METHODS: We used data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) registry to validate the THRIVE-c score in patients receiving IVT therapy. We evaluated the score performance using area under the receiver operating characteristic curve (AUC). Receiver operator characteristic curve (ROC) was used to compare THRIVE-c score performance with other scores in predicting clinical outcome and symptomatic intracranial hemorrhage (SICH). Calibration was assessed by Pearson correlation coefficient and Hosmer-Lemeshow test. RESULTS: Among the 1,128 patients receiving IVT therapy included in this study, AUC of the THRIVE-c score for 3-month SICH, poor functional outcome, and mortality rate was 0.70 (95% CI: 0.63-0.76), 0.75 (95% CI: 0.73-0.78) and 0.81 (95% CI: 0.77-0.85), respectively. The increased THRIVE-c score was associated with higher risk of developing SICH, poor functional outcome, or mortality in patients with acute ischemic stroke at 3 months after thrombolysis. The performance of the THRIVE-c score was similar to or superior to other predictive scores (THRIVE score, SEDAN score, DRAGON score, HIAT2 score). CONCLUSIONS: The THRIVE-c score reliably predicts the risks of 3-month SICH, poor functional outcome, and mortality after IVT therapy in Chinese patients with ischemic stroke.
    [Abstract] [Full Text] [Related] [New Search]